- Home
- YALA vs CMPX Comparison
YALA vs CMPX Comparison
Compare YALA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | CMPX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 927.5M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | YALA | CMPX |
|---|---|---|
| Price | $6.56 | $5.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.83 |
| AVG Volume (30 Days) | 323.6K | ★ 1.8M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | $934.41 |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $1.60 |
| 52 Week High | $9.29 | $6.88 |
Technical Indicators
Market Signals| Indicator | YALA | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 47.99 |
| Support Level | $6.04 | $4.86 |
| Resistance Level | $7.32 | $5.77 |
| Average True Range (ATR) | 0.23 | 0.30 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 77.56 | 60.17 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.